At-home ketamine is safe and effective?
Researchers associated with Mindbloom just published an article arguing that at-home ketamine-assisted therapy is not only safe but led to improvements (<50%) in depression and anxiety in 62% of participants.
july 2022
Who is going to benefit from psychedelic therapy?
Psychedelic therapy is going mainstream – it won’t be long before these therapies are rolled out in clinics across the globe once the regulations around these substances are changed.
It’s time to build psychedelic infrastructure
Health systems are unprepared to offer and meet the demand for psychedelic-assisted therapy – we can start to prepare now.
Is funding for psychedelic research changing?
The legal issues and stigma surrounding psychedelics have deterred many traditional sources from funding – now, things are changing.
The next generation of psychedelics
The next generation of psychedelics is already here – let’s take a look at the advantages and disadvantages.
The Size of the Psychedelic Market
Despite psychedelics remaining highly controlled – it hasn’t deterred investors and a sizeable market has developed.
Psychedelic Research Recap June 2022
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we’re continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.
Psychedelic Research Links July 2022
This is all the other psychedelic research that came out in July 2022 that we haven’t added to our main database.